Hua Medicine

Metabolic disease therapeutics

2552 · HKEX · China

Public Market Listing

2552HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Hua Medicine are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Dorzagliatin(Huatangning)
Phase 3
GlucokinaseSmall molecule
Type 2 Diabetes
Phase 1
GlucokinaseSmall molecule
Type 2 Diabetes

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (4)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$30M$9.1M$143M—report ↗

Hua Medicine reported revenue of $30M, up 110.2% YoY, R&D spend of $9.08M, down 45.5% YoY, and cash and equivalents of $142.79M for H1 2025.

Figures only: this period's report disclosed no narrative text

View 3 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-H1$14M$17M$184M—report ↗
2023-H1$10M$10M$122M—report ↗
2022-H1$0$11M$88M—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$69M$20M$156M—report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$36M$30M$156M—report ↗
2023-FY$11M$24M$206M—report ↗
2022-FY$2.6M$19M$70M—report ↗
2021-FY$0$29M$106M—report ↗